Answers are grounded in this paper and cite their sources.
This review highlights challenges in vaccine development for enterovirus A71, indicating critical gaps in humoral immunity strategies.
Enterovirus A71 (EV-A71) is a significant public health concern, particularly in the Asia-Pacific region, where it commonly causes hand, foot, and mouth disease outbreaks. There are no clinically available antivirals, and use of inactivated vaccine is restricted to China. This review explores patterns of humoral immune response to EV-A71, highlights critical epitopes, and discusses vaccine development. Critically, we examine the challenges facing EV vaccination strategies, as well as future directions.
No takes yet. Share an insight, caveat, or question.
Bifani et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: